PL3097197T3 - Mięśniowo-specyficzne elementy regulatorowe kwasów nukleinowych oraz sposoby i ich zastosowanie - Google Patents

Mięśniowo-specyficzne elementy regulatorowe kwasów nukleinowych oraz sposoby i ich zastosowanie

Info

Publication number
PL3097197T3
PL3097197T3 PL15703234T PL15703234T PL3097197T3 PL 3097197 T3 PL3097197 T3 PL 3097197T3 PL 15703234 T PL15703234 T PL 15703234T PL 15703234 T PL15703234 T PL 15703234T PL 3097197 T3 PL3097197 T3 PL 3097197T3
Authority
PL
Poland
Prior art keywords
muscle
methods
application
nucleic acids
regulatory elements
Prior art date
Application number
PL15703234T
Other languages
English (en)
Inventor
Thierry Vandendriessche
Marinee Chuah
Pieter De Bleser
Original Assignee
Vrije Universiteit Brussel
Vib Vzw
Universiteit Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Brussel, Vib Vzw, Universiteit Gent filed Critical Vrije Universiteit Brussel
Publication of PL3097197T3 publication Critical patent/PL3097197T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL15703234T 2014-01-21 2015-01-21 Mięśniowo-specyficzne elementy regulatorowe kwasów nukleinowych oraz sposoby i ich zastosowanie PL3097197T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14151960 2014-01-21
EP15703234.3A EP3097197B1 (en) 2014-01-21 2015-01-21 Muscle-specific nucleic acid regulatory elements and methods and use thereof
PCT/EP2015/051081 WO2015110449A1 (en) 2014-01-21 2015-01-21 Muscle-specific nucleic acid regulatory elements and methods and use thereof

Publications (1)

Publication Number Publication Date
PL3097197T3 true PL3097197T3 (pl) 2021-06-28

Family

ID=49989567

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15703234T PL3097197T3 (pl) 2014-01-21 2015-01-21 Mięśniowo-specyficzne elementy regulatorowe kwasów nukleinowych oraz sposoby i ich zastosowanie

Country Status (9)

Country Link
US (4) US11072801B2 (pl)
EP (2) EP3800261A1 (pl)
JP (4) JP6626829B2 (pl)
AU (2) AU2015208247B2 (pl)
CA (1) CA2936726C (pl)
ES (1) ES2862526T3 (pl)
PL (1) PL3097197T3 (pl)
SG (1) SG11201605906UA (pl)
WO (1) WO2015110449A1 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605906UA (en) * 2014-01-21 2016-08-30 Univ Bruxelles Muscle-specific nucleic acid regulatory elements and methods and use thereof
WO2016015810A1 (de) * 2014-07-29 2016-02-04 Merck Patent Gmbh Materialien f?r organische elektrolumineszenzvorrichtungen
EP3377042A4 (en) 2015-11-16 2019-05-29 The Research Institute at Nationwide Children's Hospital MATERIALS AND METHOD FOR THE TREATMENT OF TITIN-BASED MYOPATHIES AND OTHER TITINOPATHIES
DK3442602T3 (da) 2016-04-15 2025-05-19 Res Inst Nationwide Childrens Hospital Adeno-associeret virusvektors frigørelse af mikrodystrofin til behandling af muskeldystrofi
EP4407035A3 (en) 2016-04-15 2024-10-30 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy
EP3293259A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
WO2018162748A1 (en) 2017-03-10 2018-09-13 Genethon Treatment of glycogen storage disease iii
DK3596222T5 (da) * 2017-03-17 2024-09-02 Res Inst Nationwide Childrens Hospital Adenoassocieret virusvektorfremføring af muskelspecifik mikro-dystrophin til behandling af muskeldystrofi
MA47800A (fr) 2017-03-17 2020-01-22 Univ Newcastle Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
EP3600445A1 (en) * 2017-03-27 2020-02-05 Vrije Universiteit Brussel Diaphragm-specific nucleic acid regulatory elements and methods and use thereof
ES3065816T3 (en) 2017-06-07 2026-05-08 Regeneron Pharma Compositions and methods for internalizing enzymes
WO2019078916A1 (en) 2017-10-18 2019-04-25 Research Institute At Nationwide Children's Hospital ADENO-ASSOCIATED VIRUS VECTOR ADMINISTRATION OF MUSCLE-SPECIFIC MICRO-DYSTROPHINE TO TREAT MUSCLE DYSTROPHY
EP4635987A3 (en) 2017-10-31 2026-01-14 Vib Vzw Novel antigen-binding chimeric proteins and methods and uses thereof
AR114350A1 (es) 2018-01-31 2020-08-26 Res Institute At Nationwide Children’S Hospital Terapia genética para la distrofia muscular de cinturas del tipo 2c
MA51753A (fr) 2018-02-05 2020-12-16 Audentes Therapeutics Inc Éléments de régulation de la transcription et utilisations associées
CN120665951A (zh) * 2018-02-07 2025-09-19 吉尼松公司 杂合调控元件
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
CA3099958A1 (en) 2018-04-16 2019-10-24 The Trustees Of The University Of Pennsylvania Compositions and methods for treating duchenne muscular dystrophy
IL278393B2 (en) * 2018-05-08 2023-11-01 Univ Rutgers AAV compatible polymerization proteins bind to laminin
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
BR112020025995A2 (pt) 2018-06-18 2021-03-23 Research Institute At Nationwide Children's Hospital administração de microdistrofina músculo-específica por vetor de vírus adeno-associado para tratar a distrofia muscular
WO2020006458A1 (en) 2018-06-29 2020-01-02 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
CA3107572A1 (en) 2018-08-08 2020-02-13 Genethon Mini-gde for the treatment of glycogen storage disease iii
CA3111045A1 (en) * 2018-09-05 2020-03-12 Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft A method for engineering synthetic cis-regulatory dna
EP3870215A1 (en) 2018-10-26 2021-09-01 Vrije Universiteit Brussel New tools for improving gene therapy and use thereof
KR20210124969A (ko) * 2018-12-12 2021-10-15 솔리드 바이오사이언시즈 인크. 근이영양증의 치료를 위한 조합 요법
CA3131390A1 (en) 2019-02-26 2020-09-03 Research Institute Of Nationwide Children's Hospital Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
KR20210153069A (ko) 2019-04-19 2021-12-16 제네똥 섬유아세포 성장 인자 23 관련 저인산혈증성 질환의 유전자 요법
EP4488287A3 (en) 2019-08-21 2025-03-05 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
CN114521143B (zh) * 2019-09-19 2025-03-14 吉尼松公司 减轻fkrp心脏毒性的基因治疗表达系统
US20230089121A1 (en) * 2020-02-18 2023-03-23 Vrije Universiteit Brussel Novel combination of nucleic acid regulatory elements and methods and uses thereof
KR20220142502A (ko) 2020-02-18 2022-10-21 브리제 유니버시타이트 브루셀 근육 특이적 핵산 조절 요소 및 이의 방법 및 용도
US20210361778A1 (en) * 2020-04-06 2021-11-25 Homology Medicines, Inc. Adeno-associated virus compositions for ids gene transfer and methods of use thereof
WO2021211325A1 (en) * 2020-04-17 2021-10-21 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Crispr-inhibition for facioscapulohumeral muscular dystrophy
MX2022014255A (es) * 2020-05-14 2022-12-07 Univ Pennsylvania Composiciones utiles para el tratamiento de la enfermedad de pompe.
CN115996758A (zh) * 2020-06-19 2023-04-21 吉尼松公司 使sgcg在肌肉和心脏中充分表达的基因治疗表达系统
EP4200410A1 (en) 2020-08-24 2023-06-28 Genethon C-terminal truncated gde for the treatment of glycogen storage disease iii
CA3192120A1 (en) * 2020-09-11 2022-03-17 James A. Williams Muscle-specific hybrid promoter
US20240050591A1 (en) 2020-12-21 2024-02-15 Vrije Universiteit Brussel Cardiomyocyte-derived nucleic acid regulatory elements and methods and use thereof
EP4294459A4 (en) * 2021-02-19 2025-06-18 University Of Florida Research Foundation, Incorporated Methods and compositions to confer regulation to gene therapy cargoes by heterologous use of alternative splicing cassettes
US20240358852A1 (en) 2021-04-20 2024-10-31 Anjarium Biosciences Ag Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
US20240240179A1 (en) * 2021-05-05 2024-07-18 The General Hospital Corporation Therapy for treatment of prader-willi syndrome
AU2022297795A1 (en) * 2021-06-23 2024-01-04 AskBio Inc. Regulatory nucleic acid sequences
AR126660A1 (es) 2021-07-28 2023-11-01 Univ Brussel Vrije Mejorando la eficacia de la terapia génica dirigida a músculos
CA3224482A1 (en) * 2021-08-05 2023-02-09 Brian Kaspar Adeno-associated virus particles and methods of use thereof
US12285497B2 (en) 2021-10-15 2025-04-29 Research Institute At Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
US20230200363A1 (en) * 2021-12-23 2023-06-29 FireFrogs, Inc. Transgenic fluorescent ornamental amphibians
JP2025504404A (ja) 2022-01-14 2025-02-12 アンジャリウム バイオサイエンシズ エージー Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法
CN114231532B (zh) * 2022-02-22 2022-06-17 广州派真生物技术有限公司 在哺乳动物肌肉中特异性启动基因的启动子序列及其应用
CN119365208A (zh) 2022-04-13 2025-01-24 巴塞罗那自治大学 通过表达klotho蛋白的基因疗法治疗神经肌肉疾病
CA3252764A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale GDE truncated at the N-terminal level for the treatment of type III glycogen storage disease
WO2024064895A2 (en) * 2022-09-23 2024-03-28 Astellas Gene Therapies, Inc. Compositions and methods for the treatment of neuromuscular disorders
JP2025534666A (ja) * 2022-10-11 2025-10-17 リジェネックスバイオ インコーポレイテッド 操作された核酸調節エレメントならびにその使用方法
KR20250105716A (ko) * 2022-10-11 2025-07-08 메이라지티엑스 유케이 Ii 리미티드 간에서의 유전자 발현을 위한 핵산 조절 요소 및 사용 방법
CN115838725B (zh) * 2022-12-30 2023-09-08 广州派真生物技术有限公司 在哺乳动物心脏中特异性启动基因的启动子序列及其应用
WO2024188913A1 (en) 2023-03-10 2024-09-19 Genethon Induction of immune tolerance by aav vector comprising the combination of a liver detargeted capsid and a tandem liver-muscle specific promoter
CN121420060A (zh) 2023-06-29 2026-01-27 吉尼松公司 用于治疗糖原贮积病iii的n-端截短的糖原脱支酶
TW202546236A (zh) * 2024-01-16 2025-12-01 美商安斯泰來基因治療股份有限公司 用於治療第1型肌強直性營養不良之肌肉選擇性混合調節組合及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US503558A (en) * 1893-08-15 Treating pulverulent material with gases
US127457A (en) * 1872-06-04 Improvement in saw-swages
FR2730735B1 (fr) * 1995-02-20 1997-05-09 Pasteur Institut Sequences amplificatrices, vecteurs portant ces sequences et leurs utilisations dans des compositions pour l'expression de sequences nucleotidiques dans des cellules transfectees, applications therapeutiques et vaccinales
US20030204075A9 (en) * 1999-08-09 2003-10-30 The Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
CA2448120A1 (en) 2001-05-24 2002-11-28 Genzyme Corporation Muscle-specific expression vectors
WO2003074711A1 (en) * 2002-03-04 2003-09-12 Transgene S.A. Expression cassette for persistence of expression of a gene of interest in muscle cells
US20080039413A1 (en) * 2003-10-21 2008-02-14 Morris David W Novel compositions and methods in cancer
FR2891544A1 (fr) * 2005-09-30 2007-04-06 Genethon Ass Loi De 1901 Substrat proteique pour la detection de l'activite calpaine 3
JP2009519710A (ja) * 2005-12-16 2009-05-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 遺伝子発現調節エレメントのハイスループットでの特徴付けのための機能性アレイ
US20090018031A1 (en) 2006-12-07 2009-01-15 Switchgear Genomics Transcriptional regulatory elements of biological pathways tools, and methods
US9217020B2 (en) * 2007-04-17 2015-12-22 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
DK2282764T3 (da) 2008-04-22 2019-10-14 Vib Vzw Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf
US9353164B2 (en) * 2009-10-29 2016-05-31 Vib Vzw Cardiac-specific nucleic acid regulatory elements and methods and use thereof
CN103421786B (zh) * 2013-04-24 2015-04-22 华中农业大学 鼠肌肉分化时期特异性表达基因启动子的克隆与应用
CN103451284B (zh) 2013-08-22 2015-03-18 中国科学院生物物理研究所 一组人类心肌细胞的新型分子标记物及其应用
SG11201605906UA (en) * 2014-01-21 2016-08-30 Univ Bruxelles Muscle-specific nucleic acid regulatory elements and methods and use thereof

Also Published As

Publication number Publication date
CA2936726C (en) 2024-04-30
JP2017505126A (ja) 2017-02-16
SG11201605906UA (en) 2016-08-30
EP3097197A1 (en) 2016-11-30
EP3097197B1 (en) 2020-12-16
JP7235806B2 (ja) 2023-03-08
JP2023062192A (ja) 2023-05-02
JP2021168663A (ja) 2021-10-28
US11975078B2 (en) 2024-05-07
WO2015110449A1 (en) 2015-07-30
US10731177B2 (en) 2020-08-04
US20160340693A1 (en) 2016-11-24
US20170275649A1 (en) 2017-09-28
JP6906591B2 (ja) 2021-07-21
AU2015208247B2 (en) 2021-05-27
ES2862526T3 (es) 2021-10-07
EP3800261A1 (en) 2021-04-07
AU2021202866B2 (en) 2023-09-14
US12419972B2 (en) 2025-09-23
AU2015208247A1 (en) 2016-08-25
US20200407746A1 (en) 2020-12-31
US20210395770A1 (en) 2021-12-23
CA2936726A1 (en) 2015-07-30
US11072801B2 (en) 2021-07-27
JP2020054357A (ja) 2020-04-09
AU2021202866A1 (en) 2021-06-03
JP6626829B2 (ja) 2019-12-25

Similar Documents

Publication Publication Date Title
IL283834A (en) Modulation of stimulatory and non-stimulatory myeloid cells
IL304117A (en) Anti-pvrig antibodies and methods of use
IL282372A (en) Haploid induction compositions and methods for use therefor
IL282048A (en) Oxysterols and methods of use thereof
IL258692A (en) Additive manufacturing system and method
PL3183260T3 (pl) Modyfikowane oligonukleotydy i sposoby ich syntezy
PL3828194T3 (pl) Oksysterole i sposoby ich stosowania
SG11201605906UA (en) Muscle-specific nucleic acid regulatory elements and methods and use thereof
PL3215532T3 (pl) Przeciwciała anty-TIM3 i sposoby ich zastosowania
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
EP3461890C0 (en) TOTAL FERMENTATION OF OLIGOSACCHARIDES
PL3160498T3 (pl) Cząsteczki na bazie IL-15 i sposoby ich zastosowania
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
BR112017004648A2 (pt) simuladores mir-29 e os usos deste
PL3371206T3 (pl) Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka
IL251759B (en) Compositions and methods for treating insomnia
EP3287793A4 (en) AUTO ANALYZER AND METHOD
KR20180084747A (ko) Galgt2 유전자 치료 방법 및 물질
DE112015003387A5 (de) Aquakulturanlage und kultivierungsverfahren
PL3393468T3 (pl) Metody leczenia niedoboru odporności
BR112016025413A2 (pt) método de fabricação de um inserto e inserto
IL313083A (en) Terlipressin compositions and their methods of use
DK3204307T3 (da) Indgrebsafslørende låg og fremgangsmåde til fremstilling deraf